During Wednesday's early trading session, biotechnology company Mineralys Therapeutics, Inc. (MLYS) shares declined 2.3% following the company's pricing of its expanded $250 million equity offering at $25.50 per share. The offering is expected to close on September 4, 2025. The proceeds will be utilized to support the company's growth initiatives.